Patents by Inventor David Leggett

David Leggett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190263768
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: October 16, 2018
    Publication date: August 29, 2019
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
  • Publication number: 20190241535
    Abstract: The present invention provides a compound of the following Formula (1) or a pharmaceutically acceptable salt thereof: wherein X is an oxygen atom and the like; Y is —CO—, —SO2— and the like; R1 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkylcarbonyl group and the like; R2 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; R3, R4, R5, and R6 are independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.
    Type: Application
    Filed: November 29, 2018
    Publication date: August 8, 2019
    Inventors: Toshihiko Sone, Wataru Hirose, Naoaki Shimada, Chiang Jiaq Li, Wei Li, David Leggett
  • Publication number: 20180193303
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Application
    Filed: January 5, 2018
    Publication date: July 12, 2018
    Inventors: Chiang Jia LI, David LEGGETT, Youzhi LI, Wei LI
  • Patent number: 10017488
    Abstract: The present invention provides a compound of the following Formula (1) or a pharmaceutically acceptable salt thereof: wherein X is an oxygen atom and the like; Y is —CO—, —SO2— and the like; R1 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkylcarbonyl group and the like; R2 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; R3, R4, R5, and R6 are independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: July 10, 2018
    Assignee: Boston Biomedical, Inc.
    Inventors: Toshihiko Sone, Wataru Hirose, Naoaki Shimada, Chiang J. Li, Wei Li, David Leggett
  • Publication number: 20180098959
    Abstract: Methods comprising administration of and kits comprising at least one compound of formula (I); and at least one additional anti-cancer therapy chosen from panitumumab, cetuximab, capecitabine, CAPDX, regorafenib, and FOLFOX.
    Type: Application
    Filed: April 18, 2016
    Publication date: April 12, 2018
    Applicant: BOSTON BIOMEDICAL, INC.
    Inventors: Chiang J. LI, Youzhi LI, Laura BORODYANSKY, Yuan GAO, David LEGGETT, David P. KERSTEIN
  • Patent number: 9834532
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: December 5, 2017
    Assignee: BOSTON BIOMEDICAL, INC.
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
  • Publication number: 20170319537
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Application
    Filed: July 5, 2017
    Publication date: November 9, 2017
    Applicant: BOSTON BIOMEDICAL, INC.
    Inventors: Chiang Jia Li, David Leggett, Youzhi Li, Wei Li
  • Patent number: 9730909
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: August 15, 2017
    Assignee: BOSTON BIOMEDICAL, INC
    Inventors: Chiang Jia Li, David Leggett, Youzhi Li, Wei Li
  • Publication number: 20170197932
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrant Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: February 10, 2017
    Publication date: July 13, 2017
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
  • Publication number: 20170174646
    Abstract: The present invention provides a compound of the following Formula (1) or a pharmaceutically acceptable salt thereof: wherein X is an oxygen atom and the like; Y is —CO—, —SO2— and the like; R1 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkylcarbonyl group and the like; R2 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; R3, R4, R5, and R6 are independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.
    Type: Application
    Filed: February 6, 2015
    Publication date: June 22, 2017
    Applicant: Boston Biomedical, Inc.
    Inventors: Toshihiko SONE, Wataru HIROSE, Naoaki SHIMADA, Chiang J. LI, Wei LI, David LEGGETT
  • Publication number: 20160271099
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Application
    Filed: May 31, 2016
    Publication date: September 22, 2016
    Inventors: Chiang Jia LI, David Leggett, Youzhi LI, Wei LI
  • Patent number: 9381184
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: July 5, 2016
    Assignee: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, David Leggett, Youzhi Li, Wei Li
  • Publication number: 20160030384
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Application
    Filed: April 9, 2014
    Publication date: February 4, 2016
    Applicant: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, Wei Li, David Leggett, Youzhi Li, David Kerstein, Matt Hitron
  • Patent number: 9084766
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: July 21, 2015
    Assignee: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, David Leggett, Youzhi Li, Wei Li
  • Publication number: 20150183756
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Application
    Filed: March 10, 2015
    Publication date: July 2, 2015
    Applicant: BOSTON BIOMEDICAL, INC.
    Inventors: Chiang Jia Li, David Leggett, Youzhi Li, Wei Li
  • Publication number: 20150018410
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: September 29, 2014
    Publication date: January 15, 2015
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
  • Patent number: 8877803
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrant Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: November 4, 2014
    Assignee: Boston Biomedical, Inc.
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
  • Publication number: 20130034591
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Application
    Filed: March 21, 2011
    Publication date: February 7, 2013
    Applicant: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, David Leggett, Youzhi Li, Wei Li
  • Publication number: 20130028944
    Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.
    Type: Application
    Filed: March 21, 2011
    Publication date: January 31, 2013
    Applicant: Boston Biomedical, Inc.
    Inventors: Chiang Jia Li, David Leggett, Youzhi Li, Wei Li
  • Publication number: 20110112180
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: September 10, 2008
    Publication date: May 12, 2011
    Applicant: Boston Biomedical, Inc.
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett